CU20220027A7 - COMPUESTOS QUÍMICOS DERIVADOS SUSTITUIDOS DEL ÁCIDO PROPANOICO ÚTILES EN LA INHIBICIÓN DE INTEGRINA A4ß7 HUMANA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN - Google Patents

COMPUESTOS QUÍMICOS DERIVADOS SUSTITUIDOS DEL ÁCIDO PROPANOICO ÚTILES EN LA INHIBICIÓN DE INTEGRINA A4ß7 HUMANA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN

Info

Publication number
CU20220027A7
CU20220027A7 CU2022000027A CU20220027A CU20220027A7 CU 20220027 A7 CU20220027 A7 CU 20220027A7 CU 2022000027 A CU2022000027 A CU 2022000027A CU 20220027 A CU20220027 A CU 20220027A CU 20220027 A7 CU20220027 A7 CU 20220027A7
Authority
CU
Cuba
Prior art keywords
inhibition
pharmaceutical compositions
propanoic acid
chemical compounds
compositions containing
Prior art date
Application number
CU2022000027A
Other languages
English (en)
Inventor
Matthew G Bursavich
Dan Cui
Tyler Day
James E Dowling
Aleksey I Gerasyuto
Kristopher N Hahn
Bryce A Harrison
Eugene Hickey
Evelyne Houang
Byungchan Kim
Kyle D Konze
fu-yang Lin
Blaise S Lippa
Salma Rafi
Bruce N Rogers
Dawn M Troast
Robert Zahler
Cheng Zhong
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of CU20220027A7 publication Critical patent/CU20220027A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)

Abstract

<p>Se describen compuestos químicos derivados sustituidos del ácido propanoico de fórmula I</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>útiles en la inhibición de la integrina humana α4ß7 humana y, composiciones farmacéuticas que los contienen. </p>
CU2022000027A 2019-10-16 2020-10-16 COMPUESTOS QUÍMICOS DERIVADOS SUSTITUIDOS DEL ÁCIDO PROPANOICO ÚTILES EN LA INHIBICIÓN DE INTEGRINA A4ß7 HUMANA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN CU20220027A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
PCT/US2020/055986 WO2021076890A1 (en) 2019-10-16 2020-10-16 INHIBITING HUMAN INTEGRIN α4β7

Publications (1)

Publication Number Publication Date
CU20220027A7 true CU20220027A7 (es) 2022-12-12

Family

ID=73198501

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000027A CU20220027A7 (es) 2019-10-16 2020-10-16 COMPUESTOS QUÍMICOS DERIVADOS SUSTITUIDOS DEL ÁCIDO PROPANOICO ÚTILES EN LA INHIBICIÓN DE INTEGRINA A4ß7 HUMANA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN

Country Status (37)

Country Link
US (3) US20240174632A1 (es)
EP (3) EP4045039B1 (es)
JP (7) JP7437490B2 (es)
KR (2) KR20220102669A (es)
CN (4) CN119192137A (es)
AR (1) AR120244A1 (es)
AU (3) AU2020366435B2 (es)
BR (1) BR112022007284A2 (es)
CA (1) CA3154269A1 (es)
CL (1) CL2022000959A1 (es)
CO (1) CO2022005759A2 (es)
CR (1) CR20220205A (es)
CU (1) CU20220027A7 (es)
DK (1) DK4045039T3 (es)
DO (2) DOP2022000081A (es)
EC (1) ECSP22038978A (es)
ES (1) ES3035561T3 (es)
FI (1) FI4045039T3 (es)
HR (1) HRP20250749T1 (es)
HU (1) HUE071814T2 (es)
IL (2) IL319053A (es)
LT (1) LT4045039T (es)
MA (1) MA57399B1 (es)
MD (1) MD4045039T2 (es)
MX (1) MX2022004406A (es)
PE (1) PE20221829A1 (es)
PH (1) PH12022550886A1 (es)
PL (1) PL4045039T3 (es)
PT (1) PT4045039T (es)
PY (1) PY2065718A (es)
RS (1) RS66976B1 (es)
SI (1) SI4045039T1 (es)
TW (7) TWI775182B (es)
UA (1) UA130059C2 (es)
UY (1) UY38926A (es)
WO (3) WO2021076890A1 (es)
ZA (2) ZA202203872B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202528300A (zh) 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
BR112022007284A2 (pt) * 2019-10-16 2022-07-05 Morphic Therapeutic Inc Inibição de integrina humana alpha-4 beta-7
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
US20250195485A1 (en) * 2021-12-27 2025-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and medical use thereof
EP4585587A1 (en) 2022-09-09 2025-07-16 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and use thereof in medicine
CN120500479A (zh) 2022-12-22 2025-08-15 新特拉有限公司 α4β7整联蛋白拮抗剂及其用途
CN120957974A (zh) * 2023-02-21 2025-11-14 希四克斯探索有限公司 大环α4β7整合素抑制剂
WO2024249328A2 (en) 2023-05-26 2024-12-05 Adarx Pharmaceuticals, Inc. Sod1-modulating compositions and methods of use thereof
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2024317579A1 (en) 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018016A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
WO2026018017A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
CN119504796B (zh) * 2024-11-20 2026-03-10 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用
WO2026138844A1 (zh) * 2024-12-24 2026-07-02 湖北生物医药产业技术研究院有限公司 酰胺类化合物及其作为整合素α4β7拮抗剂的用途
WO2026156089A1 (en) 2025-01-17 2026-07-23 Eli Lilly And Company Small molecule alpha4beta7 integrin inhibitor for use in the treatment of inflammatory bowel disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425431T2 (de) 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
WO1998016524A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ES2221227T3 (es) 1997-11-24 2004-12-16 MERCK &amp; CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
SK288186B6 (sk) * 1999-05-07 2014-05-06 Encysive Pharmaceuticals, Inc. Deriváty kyseliny propiónovej, ktoré inhibujú väzbu integrínov na ich receptory, farmaceutické kompozície s ich obsahom a ich použitie
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
EP1214292B1 (en) 1999-09-24 2007-06-13 Genentech, Inc. Tyrosine derivatives
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
BR0113671A (pt) * 2000-08-30 2004-01-06 Pharmacia Corp Antagonistas de integrina alfa v beta 3 gem-substituìda
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
CA2610800A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
JP7054990B2 (ja) 2014-03-27 2022-04-15 ジェネンテック， インコーポレイテッド 炎症性腸疾患の診断及び治療のための方法
CN105658641B (zh) 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
EP3224280A1 (en) * 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
EP4159727B1 (en) * 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
TW202528300A (zh) * 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) * 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
ES2987796T3 (es) * 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
BR112022007284A2 (pt) * 2019-10-16 2022-07-05 Morphic Therapeutic Inc Inibição de integrina humana alpha-4 beta-7

Also Published As

Publication number Publication date
AU2021361031A1 (en) 2023-06-08
JP2024054296A (ja) 2024-04-16
AU2026206251A1 (en) 2026-08-06
JP7209116B2 (ja) 2023-01-19
ZA202203872B (en) 2024-01-31
CR20220205A (es) 2022-07-22
SI4045039T1 (sl) 2025-07-31
US11104661B1 (en) 2021-08-31
JP2023036958A (ja) 2023-03-14
TWI775182B (zh) 2022-08-21
ES3035561T3 (en) 2025-09-04
RS66976B1 (sr) 2025-07-31
MD4045039T2 (ro) 2025-11-30
JP7437490B2 (ja) 2024-02-22
EP4045039B1 (en) 2025-04-23
JP2024054293A (ja) 2024-04-16
EP4228634A1 (en) 2023-08-23
TWI791304B (zh) 2023-02-01
TW202126624A (zh) 2021-07-16
IL319053A (en) 2025-04-01
CN119192137A (zh) 2024-12-27
WO2021076902A1 (en) 2021-04-22
UY38926A (es) 2021-05-31
TW202500559A (zh) 2025-01-01
AU2020366435A1 (en) 2022-04-21
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
LT4045039T (lt) 2025-08-11
EP4559525A3 (en) 2025-08-20
WO2021076890A1 (en) 2021-04-22
DOP2025000034A (es) 2025-04-08
ECSP22038978A (es) 2022-06-30
PY2065718A (es) 2023-01-17
CO2022005759A2 (es) 2022-05-20
TW202315868A (zh) 2023-04-16
CN116783161A (zh) 2023-09-19
EP4045039A4 (en) 2023-12-13
TW202500558A (zh) 2025-01-01
FI4045039T3 (fi) 2025-06-20
JP7437495B2 (ja) 2024-02-22
IL292296A (en) 2022-06-01
JP2024116230A (ja) 2024-08-27
CL2022000959A1 (es) 2023-04-28
IL292296B2 (en) 2025-07-01
TWI900200B (zh) 2025-10-01
PL4045039T3 (pl) 2025-09-15
JP7702004B2 (ja) 2025-07-02
CA3154269A1 (en) 2021-04-22
KR20220102669A (ko) 2022-07-20
PH12022550886A1 (en) 2023-05-03
TW202244040A (zh) 2022-11-16
TWI888065B (zh) 2025-06-21
TW202332675A (zh) 2023-08-16
DOP2022000081A (es) 2022-07-31
UA130059C2 (uk) 2025-10-29
JP7717202B2 (ja) 2025-08-01
HUE071814T2 (hu) 2025-09-28
KR20230088376A (ko) 2023-06-19
CN115087444A (zh) 2022-09-20
AU2020366435B2 (en) 2026-05-28
TWI840047B (zh) 2024-04-21
WO2022081983A1 (en) 2022-04-21
CN115087444B (zh) 2024-09-17
JP7869261B2 (ja) 2026-06-02
US11370773B1 (en) 2022-06-28
CN116783161B (zh) 2026-04-03
IL292296B1 (en) 2025-03-01
JP2022542184A (ja) 2022-09-29
DK4045039T3 (da) 2025-06-30
TWI802477B (zh) 2023-05-11
WO2021076890A4 (en) 2021-06-10
MA57399B1 (fr) 2025-06-30
PE20221829A1 (es) 2022-11-29
JP2023500437A (ja) 2023-01-06
US20240174632A1 (en) 2024-05-30
ZA202303992B (en) 2024-06-26
CN122251398A (zh) 2026-06-23
HRP20250749T1 (hr) 2025-08-15
JP7500785B2 (ja) 2024-06-17
JP2022548809A (ja) 2022-11-22
BR112022007284A2 (pt) 2022-07-05
AR120244A1 (es) 2022-02-09
MX2022004406A (es) 2022-08-25
EP4045039A1 (en) 2022-08-24
EP4228634A4 (en) 2024-12-18
PT4045039T (pt) 2025-07-02
EP4559525B1 (en) 2026-08-05
EP4559525A2 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
CO2019005824A2 (es) Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CY1123479T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
CU24621B1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
MX376028B (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CU20180027A7 (es) DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
JOP20190174B1 (ar) مثبطات jak1 انتقائية
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
UY35275A (es) Derivados de aminopirazina
MX2019005233A (es) Pirrolamidas como inhibidores de la integrina alfa v.
MX2020003883A (es) Composiciones que contienen derivados de acido benzoico o acido furoico y uso de los derivados para estabilidad de emulsion y de espuma.
BR112017018580A2 (pt) p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
MX2018002898A (es) Compuestos utiles para inhibir ror-gamma-t.
EA201792247A1 (ru) Ингибиторы деацетилаз гистонов и композиции и способы их применения